Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.64 |
| ▸ | SLC18A3 | Q16572 | 11/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778652 | 1.00 | ESR2 (0.64) | ESR2SLC18A3SIGMAR1CYP2D6TSHR | |
| SCHEMBL557667 | 1.00 | ESR2 (0.64) | ESR2SLC18A3SIGMAR1CYP2D6TSHR | |
| SCHEMBL8727992 | 0.93 | ESR2 (0.57) | ESR2SLC18A3SIGMAR1CYP2D6TSHR | |
| SCHEMBL8727996 | 0.93 | ESR2 (0.57) | ESR2SLC18A3SIGMAR1CYP2D6TSHR | |
| Hydrogen Peroxide SCHEMBL2353767 | 0.89 | SLC18A3 (0.64) | SLC18A3SIGMAR1CYP2D6TSHRSMN1; SMN2 | |
| SCHEMBL7265967 | 0.87 | NPC1 (0.65) | ESR2SLC18A3SIGMAR1CYP2D6TSHR | |
| SCHEMBL41763 | 0.87 | — | — | |
| SCHEMBL190417 | 0.87 | SLC18A3 (0.67) | SLC18A3SIGMAR1CYP2D6SMN1; SMN2AKR1C3 | |
| SCHEMBL17730101 | 0.86 | AKR1C3 (0.57) | ESR2SLC18A3SIGMAR1CYP2D6TSHR | |
| SCHEMBL6404297 | 0.86 | ESR2 (0.57) | ESR2SLC18A3SIGMAR1CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112961194-A | PNO ligand containing chiral ferrocene and application thereof | 洛阳师范学院 | 2021-06-15 | — | — | CN | claimed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3924058-B1 | 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-01-01 | — | — | US | disclosed |
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-12-16 | — | — | US | disclosed |
| US-12331018-B2 | Pyrrolidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | MERCK SHARP & DOHME LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-12281073-B2 | Substituted piperidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-04-22 | — | — | US | disclosed |
| US-20240360081-A1 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-10-31 | — | — | US | disclosed |
| US-6251897-B1 | TREATING DERMATITIS, ASTHMA | NIKKEN CHEMICALS CO., LTD (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0928789-A1 | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ONE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0924204-A1 | 2-PHENYLMORPHOLIN-5-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5723450-A | Substituted pyridines, their preparation, and their use as pesticides and fungicides | HOECHST SCHERING AGREVO GMBH (DE) | 1998-03-03 | — | — | US | disclosed |
| US-5571815-A | Substituted pyrimidines, process for their preparation, and their use as pesticides and fungicides | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-11-05 | — | — | US | disclosed |
| CN-1130901-A | Substituted pyridines, their preparation and their use as pesticides and fungicides | HOECHST SCHERING AGREVO GMBH (DE) | 1996-09-11 | — | — | CN | disclosed |
| EP-0719256-A1 | SUBSTITUTED PYRIDINES, PROCESS FOR PRODUCING THEM AND THEIR USE AS PESTICIDES AND FUNGICIDES | Hoechst Schering AgrEvo GmbH (DE) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007891-A1 | SUBSTITUTED PYRIDINES, PROCESS FOR PRODUCING THEM AND THEIR USE AS PESTICIDES AND FUNGICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1995-03-23 | — | — | WO | disclosed |
| EP-0631575-A1 | SUBSTITUTED PYRIMIDINES AND THEIR USE AS PESTICIDES | Hoechst Schering AgrEvo GmbH (DE) | 1995-01-04 | — | — | EP | disclosed |
| WO-1993019050-A1 | SUBSTITUTED PYRIMIDINES AND THEIR USE AS PESTICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497362-B2 | Cyclopentapyrrole orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | ESR2 846/4885SLC18A3 491/4885SIGMAR1 417/4885 |
| US-20240360081-A1 | SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF | HCRTR1, HCRTR2, NPY1R | ESR2 647/4885SLC18A3 699/4885SIGMAR1 74/4885 |
| US-12552767-B2 | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, NPY1R | ESR2 589/4885SLC18A3 612/4885SIGMAR1 110/4885 |
| US-12281073-B2 | Substituted piperidine compound and use thereof | HCRTR2, HCRTR1, NTSR2 | ESR2 913/4885SLC18A3 623/4885SIGMAR1 136/4885 |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPBWR1 | ESR2 3371/4885SLC18A3 316/4885SIGMAR1 76/4885 |
| US-12312332-B2 | Heteroaryl pyrrolidine and piperidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | ESR2 609/4885SLC18A3 486/4885SIGMAR1 291/4885 |
| US-12331018-B2 | Pyrrolidine orexin receptor agonists | HCRTR2, HCRTR1, OXTR | ESR2 746/4885SLC18A3 427/4885SIGMAR1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.